Table 2. Multivariable analysis for survival outcomes.
| Characteristic | DFS | CSS | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (yr) | |||||
| <40 | 1.00 | - | 1.00 | - | |
| 40–49 | 0.97 (0.81–1.16) | 0.720 | 0.84 (0.67–1.05) | 0.120 | |
| Histology | |||||
| SCC | 1.00 | - | 1.00 | - | |
| Adenocarcinoma | 1.77 (1.43–2.19) | <0.001 | 1.56 (1.19–2.05) | 0.001 | |
| Adenosquamous | 1.47 (1.10–1.97) | 0.010 | 1.75 (1.25–2.45) | 0.001 | |
| Others | 1.56 (0.80–3.05) | 0.190 | 1.24 (0.55–2.81) | 0.610 | |
| Tumor size (cm) | |||||
| ≤4 | 1.00 | - | 1.00 | - | |
| >4 | 1.30 (1.06–1.60) | 0.012 | 1.50 (1.17–1.93) | 0.001 | |
| Parametria | |||||
| Not involved | 1.00 | - | 1.00 | - | |
| Involved | 2.16 (1.74–2.68) | <0.001 | 1.96 (1.52–2.54) | <0.001 | |
| Deep stromal invasion | |||||
| Not involved | 1.00 | - | 1.00 | - | |
| Involved | 1.65 (1.28–2.13) | <0.001 | 2.03 (1.42–2.90) | <0.001 | |
| LVSI | |||||
| No | 1.00 | - | 1.00 | - | |
| Yes | 1.90 (1.46–2.47) | <0.001 | 2.83 (1.90–4.22) | <0.001 | |
| Uterine corpus | |||||
| Not involved | 1.00 | - | 1.00 | - | |
| Involved | 0.98 (0.77–1.25) | 0.890 | 1.15 (0.87–1.51) | 0.330 | |
| Pelvic lymph node | |||||
| Not involved | 1.00 | - | 1.00 | - | |
| Involved | 2.23 (1.81–2.74) | <0.001 | 2.65 (2.04–3.44) | <0.001 | |
| Para-aortic lymph node | |||||
| Not involved | 1.00 | - | 1.00 | - | |
| Involved | 1.93 (1.22–3.06) | 0.005 | 2.45 (1.48–4.05) | 0.001 | |
| Clinically not involved | 1.07 (0.83–1.39) | 0.590 | 1.11 (0.80–1.54) | 0.550 | |
| Peritoneal cytology | |||||
| No malignancy | 1.00 | - | 1.00 | - | |
| Malignant cells | 1.05 (0.85–1.30) | 0.670 | 0.96 (0.75–1.24) | 0.770 | |
| Ovarian conservation | |||||
| No | 1.00 | - | 1.00 | - | |
| Yes | 1.85 (0.82–4.19) | 0.140 | 1.22 (0.39–3.85) | 0.740 | |
Cox proportional hazard regression model for multivariable analysis. All the listed covariates were entered in the final model. Significant p-values are emboldened.
CI, confidence interval; CSS, cause-specific survival; DFS, disease-free survival; HR, hazard ratio; LVSI, lymphovascular space invasion; SCC, squamous cell carcinoma.